Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Hodgkin Disease

Pathologic Complete Response, Rectal Neoplasms

Colorectal Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms, Neoplasm, Residual

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Lymphoma, Follicular

Carcinoma, Hepatocellular

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Neoplasms

Squamous Cell Carcinoma of External Auditory Canal

Lymphatic Metastasis

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Head and Neck Neoplasms

Gastric Cancer Peritoneal Metastases

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Hodgkin Disease, Lymphoma

Prostatic Neoplasms

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Head and Neck Neoplasms

Renal Pelvic Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Extensive Stage Lung Small Cell Cancer

Digestive System Neoplasms

Colonic Neoplasms

Small Cell Lung Carcinoma

Rectal Neoplasms

Skin Neoplasms

Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Colonic Neoplasms

Clinical Trials

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

HOVON164HL

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

TRIUNITE06

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

FMT-LUNG

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

FUTURE

HARBOR

NeoTISLEGA

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

FIL_Tisle-HL

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

MRD2START

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

HESTIA

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Tislelizumab in People With Colorectal Cancer

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

PPIO-004-EC001

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer